RxDoctor Payments Data

Chirag Dave, MD

Urology · Marietta, GANPI 1205273091

Payments from drug & device makers

$11,771in general payments, 2019–2025

Across 199 payments — averaging $59.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Coloplast$5K
  • Procept Biorobotics Corporation$1K
  • Teleflex LLC$1K
  • Endo Pharmaceuticals Inc.$453
  • Axonics, Inc.$395
  • Boston Scientific$252
  • plus $3K from 37 others

What the payments were for

  • Travel & lodging$2,63222%
  • Food & beverage$8,62073%
  • Education$5194%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,771 in reported general payments places this provider in the 75th percentile of 369 urology providers in Georgia.

See all urology providers in Georgia

Medicare billing

Part B allowed, 2024
$209,217
Medicare patients
423
Services billed
4,750

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron187$176,295
MyrbetriqMirabegron129$97,915
Testosterone36$5,226
Estradiol85$5,176
Testosterone Cypionate74$4,150
Tamsulosin Hcl432$3,810
Finasteride47$853
Cefdinir47$603
Alfuzosin Hcl ErAlfuzosin Hcl28$539
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst44$433
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip24$309
Ciprofloxacin Hcl33$272
Anastrozole61$252
Cephalexin49$213
Gabapentin23$151

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$107$176,295187 claims
Astellas Pharma US IncMyrbetriq$49$97,915129 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 369 urology providers in Georgia.

Other urology in Marietta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →